Articles from Moonwalk Biosciences

Moonwalk Biosciences, a biotechnology company developing first-in-class adipose-targeted RNA interference (RNAi) medicines for obesity and cardiometabolic diseases, today announced the closing of an oversubscribed $70 million Series B financing.

Moonwalk Biosciences, a therapeutics company leveraging epigenetic biology and AI, will present new data using its epigenetic technology at two upcoming scientific conferences, The Liver Meeting® 2024, hosted by the American Association for the Study of Liver Diseases (AASLD), and ObesityWeek® 2024, organized by The Obesity Society.

Moonwalk Biosciences, an epigenetic biology and AI company, announced today the appointment of John Liles, Ph.D., as VP Biology and Translational Science, and the formation of a world class Cardiometabolic Advisory Board. Dr. Liles brings deep experience as a drug discovery biologist with proven success advancing novel therapeutics from target discovery through IND for liver, kidney, lung and cardiovascular diseases.

Moonwalk Biosciences, a pioneering epigenetic engineering and medicine company, announced it will present data highlighting its EpiRead and EpiWrite technologies at the American Society of Gene and Cell Therapy (ASGCT) 2024 Conference, held May 7-11, 2024, in Baltimore, Maryland.

Moonwalk Biosciences, a genomic medicine company pioneering precision epigenetic medicines, today announced the completion of $57 million in seed and Series A financing from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures and YK Bioventures. The financing will support continued advancement of Moonwalk’s epigenetic profiling and engineering technology platform and progress its pipeline of epigenetic therapeutics towards the clinic.